New Delhi, 15 February (IANS). A research team led by a scientist of Indian origin has found that a drug approved by the recent US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce the risk of heart attack and stroke. Is.
More than 10,000 people participated in this international research. It was revealed that this drug called Sotagliflozin, which has also been approved for the treatment of kidney disease, can also reduce cardiovascular risk.
Sotagliflozin is a special drug that serves as an SGLT inhibitor. It prevents the action of two proteins, SGLT 1 and SGLT 2 present in the body, which control the flow of glucose and sodium within cells and is helpful in controlling blood sugar. Other SGLT 2 obstructive drugs do not affect SGLT 1 as much.
Deepak L., director of Mount Sinai Faster Heart Hospital and Professor of Cardioskular Medicine at Ekan School of Medicine in America. Bhatt said, “These results demonstrate a new mechanism of action. Using sotgliflozine, the SGLT 1 receptors present in the kidneys, intestine, heart and brain and only SGLT 2 receptors present in the kidney only to stop heart attack and The risk of stroke may decrease. “
The research was published in the magazine the Lancet Diabetes and Endocrinology, which included 10,584 patients. All these patients were suffering from chronic kidney disease, type 2 diabetes and other risk factors of heart disease. He was kept in the trial to see the effect of this drug for 16 months on an average.
The results found that the risk of death in people taking Sotagliflzine, reduced the risk of death due to heart attack, stroke and cardiovascular causes by 23%.
Dr. Bhatt said that this drug was already approved to reduce the risk of heart problems in heart disease, heart failure and type 2 diabetes patients. But new data showed that it could also reduce the risk of heart attack and stroke, which can further increase its use.
-IANS
AS/
